Eissa, Ahmed G., Gozzi, Francesca, Aloqab, Oqab, Parrish, Charlotte E., Mohamed, Nadira, Shiali, Irene, Al-Baldawi, Harith, Foster, Paul A. and Simons, Claire ![]() ![]() |
![]() |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (1MB) |
Abstract
Resistance of oestrogen receptor-positive (ER+) breast cancer, the most prevalent type of breast cancer accounting for ∼70% of all cases, to current therapies necessitates the study of alternative strategies. One promising strategy is the multi-targeting approach using dual aromatase-steroid sulfatase inhibitors (DASIs). Herein, we describe the development of DASIs using a common benzofuran pharmacophore. Triazole benzofuran sulfamates were found to have low nM aromatase (Arom) inhibitory activity but no steroid sulfatase (STS) inhibitory activity (IC50 > 10 μM); by contrast, benzofuran ketone sulfamates demonstrated low nM STS inhibitory activity but no Arom inhibitory activity (IC50 > 1 μM). The addition of a methyl group at the 3rd position of the benzofuran ring in the benzofuran ketone sulfamate 19 (R1 = CH3) had a notable effect, resulting in dual aromatase and STS inhibitory activities with the 4-chloro derivative 19b (Arom IC50 = 137 nM, STS IC50 = 48 nM) and 4-methoxy derivative 19e (Arom IC50 = 35 nM, STS IC50 = 164 nM) optimal for dual inhibition. Arom/STS inhibition results combined with molecular dynamics studies provided a clear rationale for the activity observed.
Item Type: | Article |
---|---|
Status: | In Press |
Schools: | Pharmacy |
Additional Information: | License information from Publisher: LICENSE 1: Title: cc by, Type: cc by |
Publisher: | Royal Society of Chemistry |
Date of First Compliant Deposit: | 14 February 2025 |
Date of Acceptance: | 7 January 2025 |
Last Modified: | 14 Feb 2025 11:15 |
URI: | https://orca.cardiff.ac.uk/id/eprint/176182 |
Actions (repository staff only)
![]() |
Edit Item |